Gathering the record
Relay is organizing the evidence and source boundaries.
Experimental PEGylated MGF E-peptide derivative
PEG-MGF is marketed as a longer-lasting version of an MGF E-domain peptide, but Relay found no administered human PEG-MGF trial. Human muscle studies concern the body's own IGF-1Ec/MGF expression or non-PEG laboratory peptides. Those findings are conflicting and do not validate a PEGylated commercial product.
60-Second Overview
Start with what it is, why it matters, what research has shown, and what remains unknown. The science follows after the orientation.
Start here. These four answers explain why the compound matters before the page introduces the deeper science.
PEG-MGF is a marketed name for a proposed long-lasting, chemically modified version of a muscle-related growth-factor fragment. The exact commercial identity is often unclear.
The idea comes from the body's temporary expression of a growth-factor splice variant after mechanical stress and from laboratory experiments using non-PEG fragments. Researchers would need exact-product studies to know what PEGylation changes.
No administered human PEG-MGF trial was located. Human studies measured the body's own gene expression after exercise, while cell and animal experiments used defined non-PEG peptides and produced mixed findings. Those records do not establish PEG-MGF activity.
Sequence, PEG size and attachment, purity, distribution, persistence, immune reactions, human safety, clinical benefit, route, and product consistency all remain unresolved. Endogenous expression and non-PEG experiments cannot validate a marketed PEGylated vial.
The research depth, routes, studies, and primary sources below explain how Relay knows—and where the evidence stops.
Research context
Published research has investigated this compound using the following study designs.
These records explain what researchers did. They are not instructions, recommendations, or a transferable protocol.
The closest human record measured natural muscle-gene expression after exercise; participants were not given MGF or PEG-MGF.
Reported study administration—not a recommendation.
Research at a glance
Evidence depth, confidence, and route context explain how Relay knows—not what anyone should do.
Research concerns endogenous MGF or non-PEG E-peptides; no administered human PEG-MGF study was found.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Exact PEG identity, pharmacology, exposure, and human outcomes are unknown; related laboratory findings conflict.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: The synthetic peptide appeared only in a laboratory cell experiment and was not PEGylated. This record cannot establish PEG-MGF identity, human exposure, efficacy, safety, or a preparation standard. Amounts shown describe cited research exposure—not a dosage recommendation.
Detailed evidence
Start with the strongest supported conclusion and its main uncertainty. Claim-level records below show how the evidence changes by question, population, route, formulation, and study design.
No administered human PEG-MGF evidence was identified. The closest human evidence consists of endogenous IGF-1Ec/MGF expression after exercise and laboratory exposure of human-derived muscle cells to defined non-PEG E-peptides.
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
The actual identity and pharmacology of PEG-MGF material, including peptide sequence, PEG size and attachment site, purity, tissue distribution, receptor interactions, persistence, immunogenicity, human safety, and whether any claimed muscle or recovery effect exists.
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
Questions people bring to the evidence
Research questions—not promises of benefit.
The names MGF, IGF-1Ec, MGF E-peptide, and PEG-MGF are often blurred together even though they describe different biological or manufactured entities.
A body producing a transcript after exercise does not prove that injecting a manufactured analog reproduces the same biology.
These studies provide mechanistic hypotheses for defined laboratory peptides.
The evidence is conflicting rather than a settled regeneration pathway.
Direct evidence for PEG-MGF muscle growth, recovery, performance, pharmacokinetics, or safety is absent from the located primary record.
A longer-lasting molecule is not automatically the same molecule with the same target, tissue exposure, or safety profile.
Vendor instructions do not create a validated pharmaceutical standard.
Mechanisms
MGF is a name applied to the human IGF-1Ec splice variant and, separately, to synthetic peptides derived from its E-domain. Human exercise biopsies demonstrate transient endogenous IGF-1Ec/MGF expression after damage, while several laboratory groups reported migration, progenitor-cell, or transplantation effects from defined non-PEG E-peptides. Other investigators failed to reproduce key proliferative effects, and structure-function studies show that full pro-IGF-1Ec and isolated E-domain sequences are not functionally interchangeable. PEG-MGF adds another unvalidated layer: no exact PEG architecture, comparative pharmacology, administered human trial, or approved product standard was identified.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Replication experiments in mouse myoblasts and primary human skeletal-muscle myoblasts
C2C12 cells and primary human skeletal-muscle cells
The investigators did not reproduce previously reported proliferative or differentiation effects in the tested cell systems.
Study administration: MGF-related peptide concentrations up to 500 ng/mL
Limitations: Negative cell results do not settle every possible MGF construct, but they demonstrate that the proposed biology is assay- and peptide-definition-dependent.
Laboratory exposure of primary human muscle progenitor cells from different ages
Human-derived neonatal, young-adult, and older-adult muscle cells
The synthetic E-peptide increased several progenitor-cell measures in younger cultures, with less consistent activity in older-adult cells.
Study administration: Synthetic non-PEG 24-amino-acid MGF E-peptide
Limitations: In-vitro results with a defined non-PEG peptide do not establish whole-body muscle growth, injury recovery, dosing, pharmacokinetics, or PEG-MGF activity in people.
Serial human muscle biopsies after exercise-induced damage plus synthetic MGF E-peptide experiments in mouse myoblast-like cells
10 healthy men for the biopsy component
Endogenous MGF/IGF-1Ec expression increased transiently after muscle damage. A synthetic non-PEG E-peptide showed laboratory effects distinct from mature IGF-1.
Study administration: Exercise-induced muscle damage; synthetic non-PEG MGF E-peptide was used only in laboratory cells
Limitations: The human participants were not given MGF or PEG-MGF. Endogenous transcript expression and cell-culture peptide effects do not establish an injectable PEGylated treatment.
Human myogenic precursor-cell transplantation into mice
Mouse recipients of human myogenic precursor cells
The non-PEG synthetic peptide improved engraftment-related measures in the mouse transplantation model.
Study administration: Synthetic non-PEG MGF C-terminal E-domain peptide
Limitations: A xenograft-support experiment is not a human injury-recovery, hypertrophy, or PEG-MGF efficacy trial.
In-vitro and xenograft-associated cell-migration experiments
Human myogenic precursor cells
The peptide promoted migration-related signals and appeared to act independently of the IGF-1 receptor in these experiments.
Study administration: Synthetic non-PEG MGF C-terminal E-domain peptide
Limitations: This is cell biology, not evidence that PEGylated MGF improves human muscle repair or performance.
PubMed and ClinicalTrials.gov searches for PEG-MGF
Population not stated.
Relay did not identify an administered human PEG-MGF trial or an exact registered clinical-development program.
Study administration: Not stated in the current record.
Limitations: Search audits cannot prove that no unpublished or unregistered experiment exists, but they prevent non-PEG and endogenous findings from being mislabeled as direct PEG-MGF evidence.
Safety snapshot
PEGylation can change distribution, persistence, steric interactions, immunogenicity, and bioactivity; it cannot be assumed to preserve non-PEG MGF E-peptide findings.
Mechanistic evidenceNo validated PEG architecture or comparative pharmacology was identified for commercial PEG-MGF material.
Open sourceThe current record does not support a reliable common-versus-uncommon frequency split.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
No source-qualified compound-specific warning or contraindication is encoded in the current record.
Evidence boundaryNot FDA approved; no exact administered human PEG-MGF study or validated pharmaceutical product standard identified The actual identity and pharmacology of PEG-MGF material, including peptide sequence, PEG size and attachment site, purity, tissue distribution, receptor interactions, persistence, immunogenicity, human safety, and whether any claimed muscle or recovery effect exists.
The current record does not identify a reliable compound-specific pattern of events that caused study discontinuation.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
No compound-specific patient-facing urgent-action threshold is established in the current Relay record.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
2026-07-31
2026-07-31
2017-05-01 · PMID 28471324
2014-01-15 · PMID 24253050 · DOI 10.1152/ajpendo.00408.2013
2011-04-01 · PMID 21354439 · DOI 10.1016/j.mad.2011.02.007
2010-02-01 · PMID 20130113
2009-07-01 · PMID 19567392
2007-10-01 · PMID 17845560 · DOI 10.1111/j.1600-6143.2007.01927.x
2007-06-12 · PMID 17531227 · DOI 10.1016/j.febslet.2007.05.030
2007-02-01 · PMID 17156777 · DOI 10.1016/j.yexcr.2006.10.032